Project Description
This second edition of the clinical science journal club of the EUSTAR Young Investigators (YIG) summarizes some of the recent advances in Systemic Sclerosis related Interstitial Lung Disease (SSc-ILD). ILD is a relatively frequent complication in SSc, representing one of the main causes of morbidity and mortality. Current treatments for ILD include Cyclophosphamide and more recently Mycophenolate Mofetil (MMF). New therapeutic options are now on the horizon, mainly in the category of biologic drugs or small molecules.
Only one recent study was specifically focused on the SSc-ILD progression as primary outcome: the SENSCIS trial, that demonstrated the efficacy a of Nintedanib in reducing the annual rate of decline in FCV. The results have been recently published on the New England Journal of Medicine and are summarized below. Importantly, the Food and Drug Administration has approved the drug for this indication in September 2019.